Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BIOVENTUS INC. reported revenue of $568M, down 0.9% year over year. Operating margin was 9.5% and net margin 4.0%, on a free-cash-flow margin of 12.7% with capital expenditure at 0.5% of revenue. Every figure is computed directly from BVS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $568M | 9.5% | 4.0% |
| FY2024 | $573M | -2.7% | -6.3% |
| FY2023 | $512M | -16.0% | -30.5% |
| FY2022 | $512M | -32.7% | -31.0% |
| FY2021 | $431M | 2.8% | 4.5% |
How does BVS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.